A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer.
In: Women's Health Weekly, 2024-05-28, S. 27-27
serialPeriodical
Zugriff:
This document provides information about a clinical trial, NCT06410534, that is being conducted by the National Cancer Institute (NCI) to investigate the use of immune checkpoint blockade drugs in patients with colorectal or gastroesophageal cancer. The trial aims to determine if these drugs can delay or avoid the need for surgery, which can have negative effects on patients' quality of life. Participants will receive either nivolumab alone or a combination of nivolumab and ipilimumab, and their response to treatment will be regularly evaluated. If their disease progresses, they will undergo surgery. The trial is expected to provide valuable insights into the effectiveness of these drugs in organ preservation strategies for these types of cancer. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer.
|
---|---|
Zeitschrift: | Women's Health Weekly, 2024-05-28, S. 27-27 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Sonstiges: |
|